BioVie (NASDAQ:BIVI) Releases Quarterly Earnings Results

BioVie (NASDAQ:BIVI) announced its earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, Zacks reports.

BioVie Trading Down 3.2 %

BIVI opened at $1.80 on Wednesday. The firm has a market capitalization of $31.98 million, a PE ratio of -0.16 and a beta of 0.47. BioVie has a twelve month low of $1.04 and a twelve month high of $33.10. The firm’s 50-day moving average price is $2.20 and its 200 day moving average price is $2.29.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.